Eisai EMEA
Neil Yolland is an experienced professional in business and clinical systems, currently serving as Director of Business & Clinical Systems and Head of Global Clinical Trial Transparency at Eisai EMEA since December 2010. Previously, Neil held roles such as Associate Director and Senior Manager at Eisai, where responsibilities included acting as a business & IT liaison, project management, and managing clinical system portfolios. Neil’s career began at PAREXEL as a Programmer Analyst. Neil holds a Bachelor of Science in Biological Sciences with Molecular Genetics from the University of Warwick, a PRINCE2 certification in Project Management from The Knowledge Academy, and has A Levels in Biology, Chemistry, and Pure Maths with Statistics from Barton Peveril Sixth Form College.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Eisai EMEA
3 followers
At Eisai, everything we do is dedicated to giving our first thought to patients and their families through our human health care (hhc) philosophy. We are the European hub of Tokyo-based Eisai Co. Ltd., forming part of a multinational team working across a global network of R&D facilities, manufacturing sites and marketing subsidiaries. Our collective passion and dedication to patient care is the driving force behind our efforts to discover and develop innovative medicines in a variety of therapeutic areas in which a high unmet medical need remains, including oncology and neurology. Our mission is clear; we strive to make a significant long-lasting contribution to society in an ethical, compliant and sustainable way by embodying our hhc philosophy in everything we do. For more information about Eisai in the EMEA region please visit www.eisai.eu Our community guidelines can be found here: https://www.eisai.eu/wp-content/uploads/Community-guidelines-v1.0.pdf For more information about how Eisai processes your data, please refer to our privacy policy here: https://www.eisai.eu/privacy-policy/ --- November 2023 | EMEA-NON-23-00180